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Advances in Brief
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Abstract
Microsatellite instability (MSI) and frameshift mutations in genes con-
taining nucleotide repeats have been reported in a subset of colorectal and
gastric carcinomas. This study describes the analysis of MSI-positive
colorectal (39 cases) and gastric carcinomas (36 cases) for the presence of
frameshift mutations of the six genes known to be involved in DNA repair
and containing mononucleotide repeats in their coding region. Our mu-
tational study of the 75 MSI-positive tumors revealed frequent mutations
in hRAD50 (23 cases, 31%), BLM (16 cases, 21%), and hMSH6 (16 cases,
21%); rare mutations in BRCA1 (1 case, 1%) and ATM (3 cases, 4%); and
no mutation in NBS1. In contrast, no frameshift mutation was found in 60
MSI-negative colorectal and gastric carcinomas. The mutation of
hRAD50, a gene that is involved in the response to cellular DNA damage
and forms a complex with hMRE11 and NBS1, has not been reported
previously. Our results suggest that frameshift mutations of hRAD50,
BLM, and hMSH6 are selected and play a role in the tumorigenesis of
colorectal and gastric carcinomas with MSI. The MSI targeting of the
hRAD50 and BLM genes represents an additional link between MSI and
DNA repair because alteration of these genes could accelerate defective
DNA repair.
Introduction
A subset of sporadic gastrointestinal carcinomas exhibits a molec-
ular phenotype commonly referred to as MSI.3 MSI is detected as
alterations in the size of microsatellite DNA sequences in DNA
derived from tumor and matched normal tissue. MSI is a consequence
of defects in the DNA mismatch repair genes, including hMSH2,
hMLH1, hPMS1, hPMS2, hMSH3, and hMSH6 (1). Recent studies
indicate that hMLH1 promoter hypermethylation and lack of hMLH1
expression play a major pathogenic role in sporadic tumors with MSI
(2, 3). Defective DNA mismatch repair is thought to promote tumor-
igenesis by accelerating mutations in the oncogenes and tumor sup-
pressor genes (4).
MSI has usually been demonstrated in the noncoding portions of
the genes. However, in some cancer-related genes and in some of the
mismatch repair genes, MSI has been identified in the protein coding
regions. Known target genes affected by defective mismatch repair
include TGF-bRII, IGFIIR, and BAX (5–8). Mutations targeting
monotonic runs within the two mismatch repair genes hMSH3 and
hMSH6 have also been identified in MSI-positive tumors (9). These
findings suggest a multistep progression of MSI-positive tumors, a
model in which the MSI mutator phenotype unfolds in gradual steps
by successive actions of the different mutator genes. Therefore, the
MSI-positive tumor cascade is composed of primary and secondary
mutator genes, accelerating the level of genomic instability.
It was recently reported that the DNA mismatch repair proteins
form a complex with other genes involved in DNA repair. DNA
damage repair proteins (hMSH2, hMSH6, hMLH1, ATM, and BLM),
hRAD50-hMRE11-NBS1 protein complex, and DNA replication fac-
tor C associate with BRCA1 to form a large complex named BASC
that serves as a sensor for DNA damage (10). Interestingly, many
genes in this BASC have mononucleotide repeats within the coding
regions: (a) the (A)9 tract in the hRAD50 and BLM genes; (b) the (A)8
tract in the BRCA1 gene; (c) the (C)8 tract in the hMSH6 gene; (d) the
(A)7 tract in the NBS1 gene; and (e) the (T)7 tract of the ATM gene.
Frameshift mutations of these genes, except for hRAD50, ATM, and
NBS1 in the MSI-positive tumors, had been reported previously with
variable incidences (8, 9, 11). Given that the mononucleotide repeats
in hRAD50, ATM, and NBS1 might be another important target of
tumors with MSI, we investigated the occurrence of frameshift mu-
tations in these genes and compared these results with the occurrence
of frameshift mutations in the other genes forming the BASC in
primary colorectal and gastric carcinomas with MSI.
Materials and Methods
Patients and Tissue Samples. A total of 230 colorectal carcinomas and
414 gastric carcinomas were included in this study for the selection of tumors
with MSI. All cases were identified consecutively for the Gastrointestinal
Tumor Working Group Tissue Bank at Yonsei University Medical Center
(Seoul, Korea) between December 1996 and November 1999. All cases were
histologically confirmed as adenocarcinoma by two pathologists (H. Ka. and
H. Ki.) without prior knowledge of the molecular data. Tumor specimens were
microdissected on a cryostat and fractionated to enrich the tumor cell popu-
lation. Genomic DNA was prepared by the SDS-proteinase K and phenol-
chloroform extraction method.
Screening of MSI. DNAs from colorectal carcinomas (230) and gastric
carcinomas (414) and matched normal DNAs were PCR amplified at five
microsatellite loci (BAT26, BAT25, D2S123, D5S346, and D17S250) to
evaluate MSI. PCR reactions were carried out in a mixture of 20 ml
containing 1.5 mM MgCl2; 20 pmol of primer; 0.2 mM each of dATP,
dGTP, and dTTP; 5 mM dCTP; 1 mCi of [a-32P]dCTP (3000 Ci/mmol;
DuPont New England Nuclear, Boston, MA); 50 ng of sample DNA; 13
PCR buffer; and 1.25 units of Taq DNA polymerase (Life Technologies,
Inc., Grand Island, NY). After denaturation at 95°C for 5 min, DNA
amplification was performed for 25–30 cycles consisting of denaturation at
95°C for 30 s, primer annealing at 55°C– 60°C for 30 s, and elongation at
72°C for 15 s. PCR products were separated in 6% polyacrylamide gels
containing 5.6 M urea, followed by autoradiography. MSI was determined
by the mobility shift of products from PCR. In tumors with MSI, additional
bands were found in the normal allele regions. Based on the number of
markers displaying instability per tumor, the tumors were initially divided
into three groups: (a) those with two or more of the five markers showing
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instability (high MSI, MSI-H); (b) those with one of five markers showing
instability (low MSI, MSI-L); and (c) those with no instability (MSI stable,
MSS; Ref. 12). MSI-H tumors were classified as MSI positive, and MSI-L
and MSS tumors were classified as MSI negative.
Detection of Frameshift Mutations. Frameshift mutation in the hRAD50
gene was detected using a PCR-based assay. Genomic DNA was amplified with
primers RAD50F (59-AACTGCGACTTGCTCCAGAT-39) and RAD50R (59-
CAAGTCCCAGCATTTCATCA-39) encompassing an 87-bp region of the
hRAD50 segment [codon 704–733; (A)9 repeats are located between codon 719
and 722]. Frameshift mutations of the ATM and NBS1 genes were also analyzed
using the same method. The primers for ATM were ATMF (59-CATGCTGTTAC-
CAAAGGATGC-39) and ATMR (59-TCGCACACTGAATAGCCTTG-39), en-
compassing an 88-bp region of the ATM segment [codon 192–221; (T)7 repeats are
located between codon 213 and 215], and the primers for NBS1 were NBS1F
(59-AGCAGACCAACTCCATCAGA-39) and NBS1R (59-CAGAGACAT-
GAGAGAAGTTATC-39), encompassing an 81-bp region of the NBS1 segment
[codon 450–466; (A)7 repeats are located between codon 464 and 466].
Frameshift mutations in the coding nucleotide repeats of the other genes
(BRCA1, BLM, and hMSH6) were also analyzed using a PCR-based assay by
using previously described primers (8, 11). DNA denaturation, electrophoresis,
and autoradiography were performed as described in the MSI analysis.
Sequencing Analysis of hRAD50 Frameshift Mutants. To confirm that
the shifted band represents a frameshift mutation of the hRAD50 gene,
genomic DNA fragments exhibiting bandshifts were excised and eluted from
the polyacrylamide gel and subcloned to pT7Blue vector (Novagen, Madison,
WI). Plasmids were sequenced using T7 sequencing kit (USB, Cleveland, OH)
and separated in 8% denaturing polyacrylamide gels.
Results
Frequency of MSI in Colorectal and Gastric Carcinomas. We
defined a tumor as MSI positive when two or more of the five markers
examined exhibited new microsatellite alleles in the tumor specimen
compared with the corresponding nonneoplastic tissue. The frequency of
MSI-positive tumors was higher in colorectal carcinomas than in gastric
carcinomas: MSI was found in 39 of 230 (17%) colorectal carcinomas
and in 36 of 414 (9%) gastric carcinomas (P 5 0.002, x2 test).
Mutational Analysis of hRAD50, BLM, hMSH6, BRCA1, ATM,
and NBS1 in Colorectal and Gastric Carcinomas with MSI. We
analyzed the frameshift mutations of the mononucleotide repeat se-
quences in the genes of the BASC complex by PCR amplification of
the regions comprising the (A)9 tract in the hRAD50 and BLM gene,
the (C)8 tract in the hMSH6 gene, the (A)8 tract in the BRCA1 gene,
the (T)7 tract in the ATM gene, and the (A)7 tract in the NBS1 gene
(Table 1).
Alterations of hRAD50 were found in 13 colorectal carcinomas
(33%) and 10 gastric carcinomas (28%). The alterations of the
hRAD50 included either 1- or 2-bp deletions or 1-bp insertions in the
(A)9 repeats of the coding region of the hRAD50 gene (Fig. 1).
Sequencing analysis confirmed that the deletion and insertion of
nucleotides in the polydeoxyadenosine tract from the hRAD50 gene
accounted for the observed bandshift (Fig. 2). Frameshift mutations in
the BLM gene were found in seven colorectal carcinomas (18%) and
nine gastric carcinomas (25%). All of the alterations of BLM were
1-bp deletions and were confirmed by sequencing analysis. The
hMSH6 gene microsatellite variants were found in nine colorectal
carcinomas (23%) and seven gastric carcinomas (19%). Frameshift
mutation analysis in the mononucleotide repeat sequences of the
BRCA1, ATM, and NBS1 genes revealed no mutation or rare mutation
of these genes. The BRCA1 frameshift mutation was found only in one
colorectal carcinoma (3%). The sequencing analysis of BRCA1 con-
firmed a 1-bp deletion in the tumor DNA, whereas DNA from the
matched normal mucosa showed the normal sequence, indicating that
this mutation is a somatic mutation rather than a germ-line mutation.
Similarly, ATM frameshift mutations were found in one colorectal
carcinoma (3%) and two gastric carcinomas (6%). No frameshift
mutation of the NBS1 gene was observed in MSI-positive colorectal
and gastric carcinomas. As controls, none of the 60 MSI-negative
carcinomas had mutations in any of the genes.
The overall mutational profiles of the six evaluated genes revealed
diverse combinations. Among the 75 MSI-positive carcinomas, 44
(59%) had mutations in more than 1 gene, 15 had mutations in 2
genes, and 29 had mutation in 1 gene. The mutations of hRAD50 and
BLM were not mutually exclusive. Of the 23 cases with hRAD50
mutation and the 16 cases with the BLM mutation, 5 revealed con-
comitant mutations within the same tumor.
We evaluated the homozygous and heterozygous status of the
mutations by comparing the intensity of the normal and abnormal
(shifted) band. The percentage of tumor cells, determined on the
histological slides for the tumors with mutations, was about 50–90%.
Taking the percentage of tumor cells into account, we could differ-
Fig. 2. Nucleotide sequence analysis of the representative clones of hRAD50 from
MSI-positive gastric carcinomas. Triangles pointing up or down indicate insertion or
deletion of one nucleotide in the polydeoxyadenosine mononucleotide repeats, respec-
tively.
Table 1 Frequency of frameshift mutations of the six genes involved in DNA repair in
75 MSI-positive gastrointestinal carcinomas
Gene
Type of nucleotide
repeat
Incidence of frameshift mutation
Colon [N 5 39] Stomach [N 5 36]
No. (%) No. (%)
hRAD50 (A)9 13 (33) 10 (28)
BLM (A)9 7 (18) 9 (25)
hMSH6 (C)8 9 (23) 7 (19)
BRCA1 (A)8 1 (3) 0
ATM (T)7 1 (3) 2 (6)
NBS1 (A)7 0 0
Fig. 1. Alteration of the coding polydeoxyadenosine mononucleotide repeat numbers
of the hRAD50 gene in the MSI-positive colorectal (A) and gastric carcinomas (B). N,
DNA from normal tissue; T, DNA from carcinoma tissue.
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entiate 30 homozygous mutations of 58 frameshift mutations of the
(A)10 repeats of the TGF-bRII gene from our 75 MSI-positive tumors
(data not shown). Among the frameshift mutations of the six genes in
the BASC, homozygous mutations were rare; 2 of 16 hMSH6 muta-
tions were homozygous, whereas all of the mutations of the other five
genes were heterozygous.
Discussion
In this study, we identified the hRAD50 gene as an important target
in tumors with MSI. Frameshift mutations of hRAD50 were present in
both MSI-positive colorectal and gastric carcinomas, and the fre-
quency of this mutation was higher compared with other genes of the
DNA repair system.
Alteration of the mismatch repair genes is the cause of MSI, and the
genetic progression of MSI-positive tumors has been proposed to be
based on the occurrence of accelerating mutations in tumor-related
genes, such as oncogenes, tumor suppressor genes, apoptosis-related
genes, and genes involved in DNA repair (5–9, 13–15). Several genes
involved in DNA repair contain mononucleotide repeats in the coding
region, and frameshift mutations of these regions have been reported
(8, 9). We found frequent frameshift mutations in BLM and hMSH6
and rare BRCA1 mutations in our MSI-positive tumors. We also
examined the incidence of frameshift mutations in three additional
DNA repair genes containing mononucleotide repeats in their coding
region, which have not been examined previously. We could not find
frequent frameshift mutations in the ATM and NBS1 genes, however,
frequent frameshift mutations of hRAD50 were found in MSI-positive
tumors, suggesting that hRAD50 might be another target gene in the
tumors with MSI.
All of the hRAD50 frameshift mutations found in this study were
expected to result in truncated proteins of approximately Mr 83,000
in size, as opposed to Mr 154,000 for the normal hRAD50 protein.
The expression of truncated hRAD50 protein and its direct impli-
cations in tumorigenesis should be elucidated in the future, along
with those of the other truncated proteins in the MSI-positive
tumors. Until now, functional and structural analysis of hRAD50
protein was not completely characterized. hRAD50 is a coiled-
coiled structural maintenance of chromosome-like protein with
ATP-dependent DNA binding activity (16). hRAD50 has a binding
domain of BRCA1 that is known to be located between the NH2-
terminal and the 752 amino acids located upstream from the (A)9
repeat (17). hRAD50 forms a complex with hMRE11 and NBS1
and functions in homologous recombination, activation of cell
cycle checkpoint, nonhomologous end joining, meiotic recombi-
nation, and telomere maintenance (18, 19). DNA double-strand
breaks are repaired by homologous recombination and nonhomolo-
gous end joining, and the hRAD50-MRE11-NBS1 complex is
involved in both pathways (18). Based on the aforementioned
structural and functional characteristics, the truncated proteins
from the mutated hRAD50 are expected to cause functional inter-
ference in protein complex formation with the other proteins as
well as accelerate defective DNA repair. The defective DNA repair
that arose from the abnormalities of the hRAD50-hMRE11-NBS1
protein complex will increase the genomic instability and is likely
to contribute to tumor formation and progression. The defective
formation of hRAD50-hMRE1-NBS1 protein is shown to be a
cause of Nijmegen breakage syndrome, an autosomal recessive
disorder characterized by chromosomal instability, ionizing radia-
tion sensitivity, and increased cancer incidence (20).
In addition to the frequent mutations of the hRAD50 gene, muta-
tions of the BLM and hMSH6 gene were also frequent in our MSI-
positive tumors. The hMSH6 gene, a DNA mismatch repair gene, is
known to be a secondary mutator gene. The mutations of hMSH6 in
MSI-positive tumors are proposed to accelerate genomic instability as-
sociated with MSI (9). The BLM gene is a member of the RecQ gene
family of helicases, and its germ-line mutation is responsible for Bloom
syndrome. The possible mechanisms of altered BLM in tumorigenesis,
which include disturbing DNA replication, repair, and recombination or
chromosomal segregation, had been proposed previously (11). Moreover,
Bloom syndrome is a cancer-prone disease and is well known for its
chromosomal instability. Therefore, the mutations of hRAD50 and BLM,
either single or putative, may selectively have effects on the genomic
instability associated with chromosomal instability, thus contributing to
cancer formation and/or progression.
In conclusion, we have identified frequent frameshift mutations of
hRAD50, BLM, and hMSH6 in tumors with MSI. Based on their
proposed function, the hRAD50 and BLM genes could represent an
additional link between MSI and DNA repair because MSI targeting
of these genes could accelerate defective repair of the damaged DNA.
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